Report: Johnson & Johnson negotiating deal to buy partner Pharmacyclics for more than $17B

Health care giant Johnson & Johnson reportedly is close to buying biopharmaceutical company Pharmacyclics, its longtime partner in developing blood cancer treatment Imbruvica.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.